Trial Profile
A randomized Phase II, open label multicenter cross-over study, to evaluate biomarkers, in 2nd line treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) with abiraterone and cabazitaxel
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms AbiCab
- 16 Nov 2017 Status changed from recruiting to discontinued.
- 25 Nov 2015 New trial record